The Medical Device Business Journal — Medical Device News & Articles | MassDevice
December 14, 2021 By Sean Whooley Leave a Comment
Toronto-based Xandar Kardian’s Series A round was led by Phoenix Venture Partners, Portfolio Active Aging & Longevity Fund and Taronga Ventures, among others, according to a news release.
Xandar Kardian boasts that the XK300 autonomous health monitor is the world’s first and only commercially available, contact-free, continuous vital sign monitoring system. The XK300 gained FDA 510(k) clearance as a Class II medical device in April and has 32 patents granted and 11 pending.
The contactless vital sign monitor offers accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers, the company said. Its radar technology can smart-build implementation to provide commercial and public building operators with real-time occupancy measurements for effective energy optimization.
“Our radar-based solutions are the future of healthcare and patient monitoring, allowing providers to take continuous vital sign measurements without any intervention — a true breakthrough that will save lives,” Xandar Kardian Founder & CEO Sam Yang said in the release. “The funds raised in this financing round will support the commercial rollout of our healthcare solutions and the expansion of our RealTech business in a digital-first era.”
Filed Under: Business/Financial News, Digital Health, Featured, Funding Roundup, Health Technology, News Well, Patient Monitoring Tagged With: Xandar Kardian
You must be logged in to post a comment.
Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.